Analyst Price Targets — CAI
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 7, 2026 11:00 am | — | BTIG | $33.00 | $20.00 | TheFly | Caris Life Sciences price target raised to $33 from $32 at BTIG |
| August 6, 2026 11:48 am | — | Evercore ISI | $26.00 | $16.45 | TheFly | Caris Life Sciences price target raised to $26 from $25 at Evercore ISI |
| July 6, 2026 12:41 pm | — | Evercore ISI | $25.00 | $17.71 | TheFly | Caris Life Sciences price target lowered to $25 from $30 at Evercore ISI |
| May 8, 2026 12:44 pm | Catherine Ramsey Schulte | Robert W. Baird | $22.00 | $15.97 | TheFly | Caris Life Sciences price target lowered to $22 from $28 at Baird |
| May 8, 2026 11:21 am | Mark Massaro | BTIG | $32.00 | $19.84 | TheFly | Caris Life Sciences price target lowered to $32 from $38 at BTIG |
| April 10, 2026 8:45 am | — | Piper Sandler | $21.00 | $17.89 | TheFly | Caris Life Sciences initiated with a Neutral at Piper Sandler |
| February 17, 2026 10:04 am | — | Robert W. Baird | $26.00 | $20.62 | TheFly | Caris Life Sciences initiated with an Outperform at Baird |
| January 5, 2026 2:46 pm | — | Evercore ISI | $38.00 | $26.68 | TheFly | Caris Life Sciences price target lowered to $38 from $40 at Evercore ISI |
| December 22, 2025 11:52 am | Kyle Mikson | Canaccord Genuity | $30.00 | $27.94 | TheFly | Caris Life Sciences price target raised to $30 from $28 at Canaccord |
| December 2, 2025 10:09 am | — | Canaccord Genuity | $28.00 | $26.05 | TheFly | Caris Life Sciences initiated with a Hold at Canaccord |
Latest News for CAI
Caris Life Sciences (Nasdaq:CAI), the Nasdaq-listed Techbio company, has published a study describing an artificial intelligence (AI) tool designed to help doctors choose first-line treatment for pancreatic cancer. The research, published in npj Precision Oncology, describes the development and validation of the Caris AI Insights model using outcomes from patients receiving FOLFIRINOX or gemcitabine plus…
Caris AI Insights for pancreatic cancer is proprietary, only available to Caris Life Sciences customers and not achievable through small panels IRVING, Texas, Aug. 27, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading TechBio company, today announced the publication of a study in npj Precision Oncology describing the development and validation of an AI-driven approach to optimize first-line…
Caris Life Sciences delivered another strong quarter, raising full-year guidance and expanding margins while sustaining positive free cash flow. Accelerating clinical volume growth and the commercial launch of Caris Detect reinforce the durability and breadth of CAI's growth drivers. Valuation remains attractive and CAI trades at a discount to peers, with a fair value estimate of $30 per share by 2028.
Caris Life Sciences, Inc. (CAI) Q2 2026 Earnings Call Transcript
Caris Life Sciences,?Inc. (CAI) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.54 per share a year ago.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CAI.
U.S. House Trading
No House trades found for CAI.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.